Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Dara plus dex in R/R myeloma patients with renal impairment

Efstathios Kastritis • 11 Dec 2020
ASH 2020
Multiple Myeloma Antibodies Daratumumab Dexamethasone
DARE

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of the Phase II DARE study (NCT03450057), investigating the combination of daratumumab (dara) and dexamethasone (dex) in patients with relapsed/refractory (R/R) multiple myeloma with renal impairment. The study found that dara+dex achieved rapid hematologic responses in patients with R/R myeloma and severe renal impairments, with many patients also experiencing a major renal response. This line of treatment also resulted in impressive progression-free survival rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Efstathios Kastritis

1:45
Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis • 27 Sep 2023
2:14
Managing renal failure in patients with multiple myeloma
Efstathios Kastritis • 27 Sep 2023
1:04
Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis • 27 Sep 2023
1:30
AL amyloidosis: current and prospective treatments
Efstathios Kastritis • 10 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals